BATM has unveiled a molecular diagnostics kit that utilises a self-collected saliva specimen to test for SARS-CoV-2 (Covid-19).
Compared to present swabbing methods, the saliva-based RT-PCR test can enhance the sample collection process and turnaround time while ensuring diagnostic accuracy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new kit is part of Adaltis’s MOLgen product range, and is comprised of reagents developed to precisely identify SARS-CoV-2 in a saliva specimen collected by a person chewing a cotton ball for 30 seconds and then spitting it (or spitting directly) into a small plastic collector tube (Salivette).
It ensures the highest levels of diagnostic accuracy using the RT-PCR technique versus other saliva-based tests presently available in the market that mainly use the lateral flow method. It can be less precise producing false negatives and positives.
The latest kits’ reagents are based on the group’s present Covid-19 antigen kit that tests specimen obtained by swabbing the upper and middle parts of the throat or fluid from the lungs.
In addition, it has five gene discovery capability to aid in identifying even with a reduced viral load and 100% accuracy for specificity and sensitivity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAs people can self-collect a saliva sample, the test can be carried out without requiring any trained healthcare staffs in full-body personal protective equipment.
As the test is non-invasive, it has particular benefits for children and individuals with disabilities.
Furthermore, processing times at the lab are significantly shorter as the test does not require expensive RNA extraction, which is a major reason for contaminations that cause false diagnoses.
This CE-certified kit can also detect all-known Covid-19 variants, including asymptomatic individuals.
BATM CEO Dr Zvi Marom said: “We are extremely proud to have launched this new saliva-based Covid-19 test for samples that are self-collected without the need for swabbing.
“This greatly simplifies the testing process to increase speed and reduce cost while maintaining the same high level of diagnostic accuracy.”
